NEW YORK – Investment bank William Blair on Monday upgraded Meridian Bioscience's shares to Outperform from a prior Market Perform rating.
In an analyst note, Brian Weinstein called Meridian an "overlooked beneficiary" from the SARS-CoV-2 pandemic, noting in particular that the Cincinnati-based firm is providing essential components for many molecular and serology tests. This the first time William Blair has upgraded Meridian's shares to Outperform in more than 10 years, Weinstein added.